Prognostic indicators for neuroblastoma: stage, grade, DNA ploidy, MIB-1-proliferation index, p53, HER-2/neu and EGFr--a survival study

J Surg Oncol. 1995 May;59(1):21-7. doi: 10.1002/jso.2930590107.


Neuroblastoma, a tumor of the sympathetic nervous system, is one of the most common solid malignancies in infants and represents 7% of all cases of childhood cancer outside of the central nervous system. Thirty-five samples of neuroblastoma from 31 patients were obtained from Duke University Medical Center between 1979 and 1991 and studied to determine the relative prognostic value of a number of clinical, histologic, nuclear, and oncogenic features. The features studied were: stage, Shimada classification, DNA ploidy, MIB-1-proliferation index and status for HER-2/neu, p53 and epidermal growth factor receptor (EGFr). Only age (P = .03), HER-2/neu (P = .01), and p53 (P = .02) reached statistical significance as prognostic indicators. The median survival for patients with HER-2/neu expression was 12 months; median survival for patients with no HER-2/neu expression was 138 months. Similarly, the median survival for patients with p53 expression was 12 months; patients with no p53 expression had a median survival was 144 months. The combination of either HER-2/neu or p53 positivity was especially strong as a prognostic indicator (P = .002).

MeSH terms

  • Antibodies, Monoclonal
  • Cell Division
  • Child, Preschool
  • DNA, Neoplasm / genetics*
  • ErbB Receptors / analysis*
  • Female
  • Humans
  • Male
  • Neoplasm Staging
  • Neuroblastoma / genetics
  • Neuroblastoma / mortality*
  • Neuroblastoma / pathology
  • Nuclear Proteins / analysis
  • Paraffin Embedding
  • Ploidies*
  • Prognosis
  • Receptor, ErbB-2 / analysis*
  • Survival Analysis
  • Tumor Suppressor Protein p53 / analysis*


  • Antibodies, Monoclonal
  • DNA, Neoplasm
  • Nuclear Proteins
  • Tumor Suppressor Protein p53
  • ErbB Receptors
  • Receptor, ErbB-2